Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • Publication number: 20220372148
    Abstract: An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.
    Type: Application
    Filed: July 3, 2020
    Publication date: November 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya SHIMBO
  • Publication number: 20220363684
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: January 7, 2022
    Publication date: November 17, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 11479550
    Abstract: A compound represented by general formula (I): (wherein in the formula, all the symbols have the same meanings as those described in the specification), or a pharmaceutically acceptable salt thereof is useful as a medicament's active ingredient having an EP4 receptor antagonistic activity, in preventing and/or treating disease caused by activation of an EP4 receptor.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: October 25, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Kousuke Tani, Satonori Higuchi
  • Publication number: 20220332825
    Abstract: A PD-1/CD4 bispecific protein for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases, hematological cancer and the like, which can reduce the induction of cytokine production or release upon administration, and thus is expected to inhibit the development of infusion reactions or cytokine release syndrome after administration.
    Type: Application
    Filed: August 7, 2020
    Publication date: October 20, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA
  • Patent number: 11471436
    Abstract: A compound represented by general formula (I) wherein all the symbols are as defined in the specification has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e. g., neurodegenerative disease such as schizophrenia.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 18, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kensuke Kusumi, Haruto Kurata, Atsushi Naganawa, Yasuyo Kodera, Yuichi Inagaki, Hiroya Takizawa, Mark Allan Wolf, Joseph Raker
  • Publication number: 20220306640
    Abstract: A compound of formula (I-a): wherein the symbols are defined in the specification, and which has a strong DDR1 inhibitory activity, and can be a therapeutic agent for DDR1-related diseases, for example, a cancer, a kidney disease, a cardiovascular disease, a central nervous system disease, or fibrosis.
    Type: Application
    Filed: September 4, 2020
    Publication date: September 29, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Yota NISHIOKA, Masakuni KURONO, Rena NISHIZAWA, Balachandra BANDODKAR, Xuechao GAO, Zhilong WAN, Ranran LV, Kevin DOYLE, Michael GOLDSMITH
  • Publication number: 20220289751
    Abstract: The compound disclosed is a KDM5 inhibitor represented by the general formula (Z): wherein all symbols have the same meanings as the definitions described in the specification, or a salt thereof, and is useful as a prophylactic and/or therapeutic agent for cancer, Huntington's disease, or Alzheimer's disease and the like.
    Type: Application
    Filed: July 16, 2020
    Publication date: September 15, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akito KAKUUCHI, Shuhei UMEMURA, Mats SVENSSON, Anatoly RUVINSKY, Daigo INOYAMA, Goran KRILOV, Hidenori TAKAHASHI, Kyle KONZE, Andreas VERRAS, Simon CRUMPLER, Maelle VALLADE, Calum MACLEOD, James N. SANDERSON, Richard J. BULL, Simon GAINES
  • Publication number: 20220283167
    Abstract: A method for identifying a patient with malignant tumor which can be expected to benefit more from an immune checkpoint inhibitor, and agent for suppressing the progression of, suppressing the recurrence of, and/or treating malignant tumor, being prescribed based thereon, comprising use of a combination of two sets of evaluation items and specific condition defined by each of combination thereof.
    Type: Application
    Filed: August 4, 2020
    Publication date: September 8, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., NATIONAL CANCER CENTER
    Inventors: Hiroyoshi NISHIKAWA, Yukiya OHYAMA, Atsushi HONDA, Atsushi OYAGI, Toru KAKINUMA, Masayuki MURATA
  • Publication number: 20220281977
    Abstract: A PD-1/CD3 bispecific antibody or an antigen-binding fragment thereof useful for preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases is disclosed. The PD-1/CD3 bispecific antibody comprises a first arm specifically binding to PD-1 and a second arm specifically binding to CD3. The PD-1/CD3 bispecific antibody can be formulated into a formulation which can reduce the occurrence of adverse reactions called as infusion reaction or cytokine release syndrome and the bispecific antibody contributes to enhancement or duration of an effect of preventing, suppressing the progression of symptoms of or the recurrence of or treating autoimmune diseases.
    Type: Application
    Filed: July 29, 2020
    Publication date: September 8, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Takuya SHIMBO, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER
  • Publication number: 20220227887
    Abstract: An immunosuppressant containing a bispecific molecule including a first binding site that specifically binds to LAG3 and a second binding site that specifically binds to CD3 or CD8.
    Type: Application
    Filed: June 10, 2020
    Publication date: July 21, 2022
    Applicants: ONO PHARMACEUTICAL CO., LTD., TOKUSHIMA UNIVERSITY
    Inventors: Taku OKAZAKI, Daisuke SUGIURA, II-mi OKAZAKI, Shiro SHIBAYAMA
  • Publication number: 20220204468
    Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
    Type: Application
    Filed: March 15, 2022
    Publication date: June 30, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Keisuke HANADA, Satonori HIGUCHI, Atsushi NAGANAWA, Yasuhiro TAKEDA
  • Publication number: 20220185885
    Abstract: An agent for preventing, suppressing the progression of symptoms of, suppressing the recurrence of or treating autoimmune diseases, comprising a bispecific antibody or an antibody fragment thereof, having a first arm specifically binding to PD-1 and a second arm specifically binding to CD19, as described herein.
    Type: Application
    Filed: April 3, 2020
    Publication date: June 16, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Tomoya TEZUKA, Mark THROSBY, Cornelis Adriaan DE KRUIF, Pieter Fokko VAN LOO, Rinse KLOOSTER, Robertus Cornelis ROOVERS
  • Publication number: 20220177474
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: February 24, 2022
    Publication date: June 9, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • Patent number: 11319296
    Abstract: An object of the present invention is to provide a DP receptor antagonist. A compound represented by general formula (I): (wherein all symbols are as shown in the specification) and a pharmaceutically acceptable salt thereof have DP receptor antagonistic activity and are also highly safe, and thus are useful as active ingredients of pharmaceuticals for DP receptor-mediated diseases. In addition, the compound represented by the general formula (I) and the pharmaceutically acceptable salt thereof also have good transferability to the central nervous system, and thus are particularly useful as a preventive and/or therapeutic agent for diseases associated with DP receptors present in the central nervous system among DP receptor-mediated diseases, that is, sleep-wake disorders.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: May 3, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki Asada, Keisuke Hanada, Satonori Higuchi, Atsushi Naganawa, Yasuhiro Takeda
  • Publication number: 20220117933
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Applicants: Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • Patent number: 11292795
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: April 5, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Publication number: 20220089532
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Application
    Filed: December 7, 2021
    Publication date: March 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji NOJIMA, Kenji SASAKI, Tohru KAMBE, Takashi KONEMURA, Yoshikazu GOTO
  • Publication number: 20220087987
    Abstract: The present invention provides a method for treating SWI/SNF complex-deficient cancers comprising a glutathione (GSH) metabolic pathway inhibitor, a pharmaceutical composition comprising a glutathione (GSH) metabolic pathway inhibitor for therapy in SWI/SNF complex-deficient cancers, and a glutathione (GSH) metabolic pathway inhibitor for use in treating SWI/SNF complex-deficient cancers. The present invention also provides a method for detecting and/or selecting a susceptible patient to a glutathione (GSH) metabolic pathway inhibitor.
    Type: Application
    Filed: December 16, 2019
    Publication date: March 24, 2022
    Applicants: National Cancer Center, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Hideaki OGIWARA, Takashi KOHNO, Hiroki SASAKI
  • Patent number: 11261154
    Abstract: A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 1, 2022
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shoji Nojima, Kenji Sasaki, Tohru Kambe, Takashi Konemura, Yoshikazu Goto
  • Publication number: 20220055986
    Abstract: A compound represented by the general formula (V) wherein all the symbols are as defined in the specification, has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Toshihide WATANABE, Kensuke KUSUMI, Satomi IMAIDE, Toshimitsu ENDO, Takaki KOMIYA, Naomi TSUBURAYA